Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dual FDA Advisory Committee Reviews Shaping Up To Be A Showdown For Dueling Merck And Vertex Hepatitis C Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Approval is widely assumed for both boceprevir and telaprevir, but there is still much to be discussed about the devilish details. Additional data coming out at European liver meeting should also be informative.
Advertisement

Related Content

Merck's Victrelis Beats Vertex's Incivek To Lucrative EU HepC Market
Merck To Ship Hepatitis C Drug Victrelis To Pharmacies Within A Week
Merck To Ship Hepatitis C Drug Victrelis To Pharmacies Within A Week
FDA May Grant Advantages For Vertex's Telaprevir Over Merck's Boceprevir
Cure Rates Hold Up Across Genetic Status For Vertex's Telaprevir
Merck May Be Positioned For First Approval Of A Protease Inhibitor In HCV
Merck May Be Positioned For First Approval Of A Protease Inhibitor In HCV
Vertex, Merck Face Education Challenge With Complex Hep C Regimens
Boceprevir Hep C Response-Guided Therapy Works For Experienced Patients
Third Telaprevir Pivotal Study Raises Bar For Competitors Another Notch

Topics

Advertisement
UsernamePublicRestriction

Register

PS071954

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel